

Mark J Levis

List of Publications by Citations

Source: <https://exaly.com/author-pdf/7407401/mark-j-levis-publications-by-citations.pdf>

Version: 2024-04-28

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

184
papers

12,168
citations

57
h-index

109
g-index

191
ext. papers

14,192
ext. citations

4.8
avg, IF

6.57
L-index

#	Paper	IF	Citations
184	Single-agent CEP-701, a novel FLT3 inhibitor, shows biologic and clinical activity in patients with relapsed or refractory acute myeloid leukemia. <i>Blood</i> , 2004 , 103, 3669-76	2.2	542
183	Validation of ITD mutations in FLT3 as a therapeutic target in human acute myeloid leukaemia. <i>Nature</i> , 2012 , 485, 260-3	50.4	525
182	AC220 is a uniquely potent and selective inhibitor of FLT3 for the treatment of acute myeloid leukemia (AML). <i>Blood</i> , 2009 , 114, 2984-92	2.2	450
181	Gilteritinib or Chemotherapy for Relapsed or Refractory -Mutated AML. <i>New England Journal of Medicine</i> , 2019 , 381, 1728-1740	59.2	413
180	Targeting the leukemia microenvironment by CXCR4 inhibition overcomes resistance to kinase inhibitors and chemotherapy in AML. <i>Blood</i> , 2009 , 113, 6215-24	2.2	410
179	A FLT3-targeted tyrosine kinase inhibitor is cytotoxic to leukemia cells in vitro and in vivo. <i>Blood</i> , 2002 , 99, 3885-91	2.2	401
178	A phase 2 trial of the FLT3 inhibitor lestaurtinib (CEP701) as first-line treatment for older patients with acute myeloid leukemia not considered fit for intensive chemotherapy. <i>Blood</i> , 2006 , 108, 3262-70	2.2	339
177	Targeting FLT3 mutations in AML: review of current knowledge and evidence. <i>Leukemia</i> , 2019 , 33, 299-310.	7	324
176	Results from a randomized trial of salvage chemotherapy followed by lestaurtinib for patients with FLT3 mutant AML in first relapse. <i>Blood</i> , 2011 , 117, 3294-301	2.2	323
175	Selective inhibition of FLT3 by gilteritinib in relapsed or refractory acute myeloid leukaemia: a multicentre, first-in-human, open-label, phase 1-2 study. <i>Lancet Oncology</i> , 2017 , 18, 1061-1075	21.7	305
174	Phase I/II study of combination therapy with sorafenib, idarubicin, and cytarabine in younger patients with acute myeloid leukemia. <i>Journal of Clinical Oncology</i> , 2010 , 28, 1856-62	2.2	298
173	Phase 2 study of azacytidine plus sorafenib in patients with acute myeloid leukemia and FLT-3 internal tandem duplication mutation. <i>Blood</i> , 2013 , 121, 4655-62	2.2	296
172	Phase I study of quizartinib administered daily to patients with relapsed or refractory acute myeloid leukemia irrespective of FMS-like tyrosine kinase 3-internal tandem duplication status. <i>Journal of Clinical Oncology</i> , 2013 , 31, 3681-7	2.2	278
171	Risk-stratified outcomes of nonmyeloablative HLA-haploidentical BMT with high-dose posttransplantation cyclophosphamide. <i>Blood</i> , 2015 , 125, 3024-31	2.2	212
170	In vitro studies of a FLT3 inhibitor combined with chemotherapy: sequence of administration is important to achieve synergistic cytotoxic effects. <i>Blood</i> , 2004 , 104, 1145-50	2.2	192
169	Pim-1 is up-regulated by constitutively activated FLT3 and plays a role in FLT3-mediated cell survival. <i>Blood</i> , 2005 , 105, 1759-67	2.2	187
168	FLT3-mutant allelic burden and clinical status are predictive of response to FLT3 inhibitors in AML. <i>Blood</i> , 2010 , 115, 1425-32	2.2	185

167	FLT3 ligand impedes the efficacy of FLT3 inhibitors in vitro and in vivo. <i>Blood</i> , 2011 , 117, 3286-93	2.2	184
166	Quizartinib versus salvage chemotherapy in relapsed or refractory FLT3-ITD acute myeloid leukaemia (QuANTUM-R): a multicentre, randomised, controlled, open-label, phase 3 trial. <i>Lancet Oncology, The</i> , 2019 , 20, 984-997	21.7	182
165	Phase I trial of maintenance sorafenib after allogeneic hematopoietic stem cell transplantation for fms-like tyrosine kinase 3 internal tandem duplication acute myeloid leukemia. <i>Biology of Blood and Marrow Transplantation</i> , 2014 , 20, 2042-8	4.7	178
164	Crenolanib is a potent inhibitor of FLT3 with activity against resistance-conferring point mutants. <i>Blood</i> , 2014 , 123, 94-100	2.2	175
163	A FLT3 tyrosine kinase inhibitor is selectively cytotoxic to acute myeloid leukemia blasts harboring FLT3 internal tandem duplication mutations. <i>Blood</i> , 2001 , 98, 885-7	2.2	174
162	Plasma inhibitory activity (PIA): a pharmacodynamic assay reveals insights into the basis for cytotoxic response to FLT3 inhibitors. <i>Blood</i> , 2006 , 108, 3477-83	2.2	172
161	FLT3 ligand causes autocrine signaling in acute myeloid leukemia cells. <i>Blood</i> , 2004 , 103, 267-74	2.2	166
160	Outcomes of Nonmyeloablative HLA-Haploidentical Blood or Marrow Transplantation With High-Dose Post-Transplantation Cyclophosphamide in Older Adults. <i>Journal of Clinical Oncology</i> , 2015 , 33, 3152-61	2.2	165
159	FLT3 mutations in acute myeloid leukemia: what is the best approach in 2013?. <i>Hematology American Society of Hematology Education Program</i> , 2013 , 2013, 220-6	3.1	164
158	FLT3 inhibition selectively kills childhood acute lymphoblastic leukemia cells with high levels of FLT3 expression. <i>Blood</i> , 2005 , 105, 812-20	2.2	164
157	Detection of FLT3 internal tandem duplication and D835 mutations by a multiplex polymerase chain reaction and capillary electrophoresis assay. <i>Journal of Molecular Diagnostics</i> , 2003 , 5, 96-102	5.1	147
156	Midostaurin approved for FLT3-mutated AML. <i>Blood</i> , 2017 , 129, 3403-3406	2.2	145
155	Quizartinib, an FLT3 inhibitor, as monotherapy in patients with relapsed or refractory acute myeloid leukaemia: an open-label, multicentre, single-arm, phase 2 trial. <i>Lancet Oncology, The</i> , 2018 , 19, 889-903	21.7	145
154	Preclinical studies of gilteritinib, a next-generation FLT3 inhibitor. <i>Blood</i> , 2017 , 129, 257-260	2.2	144
153	A pharmacodynamic study of the FLT3 inhibitor KW-2449 yields insight into the basis for clinical response. <i>Blood</i> , 2009 , 113, 3938-46	2.2	144
152	Prolonged exposure to FLT3 inhibitors leads to resistance via activation of parallel signaling pathways. <i>Blood</i> , 2007 , 109, 1643-52	2.2	132
151	Internal tandem duplication mutation of FLT3 blocks myeloid differentiation through suppression of C/EBPalpha expression. <i>Blood</i> , 2004 , 103, 1883-90	2.2	132
150	Single-agent GVHD prophylaxis with posttransplantation cyclophosphamide after myeloablative, HLA-matched BMT for AML, ALL, and MDS. <i>Blood</i> , 2014 , 124, 3817-27	2.2	128

149	The evolving role of FLT3 inhibitors in acute myeloid leukemia: quizartinib and beyond. <i>Therapeutic Advances in Hematology</i> , 2014 , 5, 65-77	5.7	128
148	FLT3 inhibitors for acute myeloid leukemia: a review of their efficacy and mechanisms of resistance. <i>International Journal of Hematology</i> , 2013 , 97, 683-94	2.3	127
147	Terminal myeloid differentiation in vivo is induced by FLT3 inhibition in FLT3/ITD AML. <i>Blood</i> , 2012 , 120, 4205-14	2.2	122
146	Comparable composite endpoints after HLA-matched and HLA-haploidentical transplantation with post-transplantation cyclophosphamide. <i>Haematologica</i> , 2017 , 102, 391-400	6.6	119
145	Internal tandem duplications of the FLT3 gene are present in leukemia stem cells. <i>Blood</i> , 2005 , 106, 673-80		115
144	Phase I/II trial of the combination of midostaurin (PKC412) and 5-azacytidine for patients with acute myeloid leukemia and myelodysplastic syndrome. <i>American Journal of Hematology</i> , 2015 , 90, 276-81 ¹	7.1	114
143	Role of allogeneic transplantation for FLT3/ITD acute myeloid leukemia: outcomes from 133 consecutive newly diagnosed patients from a single institution. <i>Biology of Blood and Marrow Transplantation</i> , 2011 , 17, 1404-9	4.7	107
142	Heterogeneous resistance to quizartinib in acute myeloid leukemia revealed by single-cell analysis. <i>Blood</i> , 2017 , 130, 48-58	2.2	100
141	A randomized assessment of adding the kinase inhibitor lestaurtinib to first-line chemotherapy for FLT3-mutated AML. <i>Blood</i> , 2017 , 129, 1143-1154	2.2	99
140	Phase 2b study of 2 dosing regimens of quizartinib monotherapy in -ITD-mutated, relapsed or refractory AML. <i>Blood</i> , 2018 , 132, 598-607	2.2	94
139	Final Results of a Phase 2 Open-Label, Monotherapy Efficacy and Safety Study of Quizartinib (AC220) in Patients with FLT3-ITD Positive or Negative Relapsed/Refractory Acute Myeloid Leukemia After Second-Line Chemotherapy or Hematopoietic Stem Cell Transplantation. <i>Blood</i> , 2012 , 120, 673-673	2.2	81
138	Pediatric AML primary samples with FLT3/ITD mutations are preferentially killed by FLT3 inhibition. <i>Blood</i> , 2004 , 104, 1841-9	2.2	77
137	Inhibition of c-Kit by tyrosine kinase inhibitors. <i>Haematologica</i> , 2015 , 100, e77-9	6.6	76
136	Bone marrow stroma-mediated resistance to FLT3 inhibitors in FLT3-ITD AML is mediated by persistent activation of extracellular regulated kinase. <i>British Journal of Haematology</i> , 2014 , 164, 61-72	4.5	72
135	FLT3 tyrosine kinase inhibitors in acute myeloid leukemia: clinical implications and limitations. <i>Leukemia and Lymphoma</i> , 2014 , 55, 243-55	1.9	70
134	A next-generation sequencing-based assay for minimal residual disease assessment in AML patients with -ITD mutations. <i>Blood Advances</i> , 2018 , 2, 825-831	7.8	69
133	Results of a Phase II Study of Crenolanib in Relapsed/Refractory Acute Myeloid Leukemia Patients (Pts) with Activating FLT3 Mutations. <i>Blood</i> , 2014 , 124, 389-389	2.2	69
132	FLT3 tyrosine kinase inhibitors. <i>International Journal of Hematology</i> , 2005 , 82, 100-7	2.3	62

131	Targeting FLT3 to treat leukemia. <i>Expert Opinion on Therapeutic Targets</i> , 2015 , 19, 37-54	6.4	60
130	Donor cell leukemia arising from clonal hematopoiesis after bone marrow transplantation. <i>Leukemia</i> , 2016 , 30, 1916-1920	10.7	59
129	Advances in targeted therapy for acute myeloid leukaemia. <i>British Journal of Haematology</i> , 2018 , 180, 484-500	4.5	59
128	Prospective study of nonmyeloablative, HLA-mismatched unrelated BMT with high-dose posttransplantation cyclophosphamide. <i>Blood Advances</i> , 2017 , 1, 288-292	7.8	58
127	Crenolanib besylate, a type I pan-FLT3 inhibitor, to demonstrate clinical activity in multiply relapsed FLT3-ITD and D835 AML. <i>Journal of Clinical Oncology</i> , 2016 , 34, 7008-7008	2.2	55
126	Sorafenib Combined with 5-azacytidine in Older Patients with Untreated FLT3-ITD Mutated Acute Myeloid Leukemia. <i>American Journal of Hematology</i> , 2018 , 93, 1136-1141	7.1	54
125	Final Results of a Phase 2 Open-Label, Monotherapy Efficacy and Safety Study of Quizartinib (AC220) in Patients ≥60 Years of Age with FLT3 ITD Positive or Negative Relapsed/Refractory Acute Myeloid Leukemia. <i>Blood</i> , 2012 , 120, 48-48	2.2	54
124	How I treat FLT3-mutated AML. <i>Blood</i> , 2017 , 129, 565-571	2.2	52
123	Randomized phase II study of two schedules of flavopiridol given as timed sequential therapy with cytosine arabinoside and mitoxantrone for adults with newly diagnosed, poor-risk acute myelogenous leukemia. <i>Haematologica</i> , 2012 , 97, 1736-42	6.6	50
122	FLT3/ITD AML and the law of unintended consequences. <i>Blood</i> , 2011 , 117, 6987-90	2.2	49
121	A potential therapeutic target for FLT3-ITD AML: PIM1 kinase. <i>Leukemia Research</i> , 2012 , 36, 224-31	2.7	45
120	A phase 2 study incorporating sorafenib into the chemotherapy for older adults with -mutated acute myeloid leukemia: CALGB 11001. <i>Blood Advances</i> , 2017 , 1, 331-340	7.8	42
119	FLT3 inhibitors: a story of the old and the new. <i>Current Opinion in Hematology</i> , 2011 , 18, 71-6	3.3	41
118	Incorporating FLT3 inhibitors into acute myeloid leukemia treatment regimens. <i>Leukemia and Lymphoma</i> , 2008 , 49, 852-63	1.9	41
117	A Phase 1 Study of the PARP Inhibitor Veliparib in Combination with Temozolomide in Acute Myeloid Leukemia. <i>Clinical Cancer Research</i> , 2017 , 23, 697-706	12.9	40
116	Quizartinib for the treatment of FLT3/ITD acute myeloid leukemia. <i>Future Oncology</i> , 2014 , 10, 1571-9	3.6	38
115	Integration of Hedgehog and mutant FLT3 signaling in myeloid leukemia. <i>Science Translational Medicine</i> , 2015 , 7, 291ra96	17.5	37
114	FLT3 inhibitor-induced neutrophilic dermatosis. <i>Blood</i> , 2013 , 122, 239-42	2.2	35

113	Gilteritinib: potent targeting of FLT3 mutations in AML. <i>Blood Advances</i> , 2020 , 4, 1178-1191	7.8	35
112	The Future of Targeting FLT3 Activation in AML. <i>Current Hematologic Malignancy Reports</i> , 2017 , 12, 153-167	4.7	32
111	FLT3 Tyrosine Kinase Inhibition as a Paradigm for Targeted Drug Development in Acute Myeloid Leukemia. <i>Seminars in Hematology</i> , 2015 , 52, 193-9	4	32
110	Mechanisms of Resistance to FLT3 Inhibitors and the Role of the Bone Marrow Microenvironment. <i>Hematology/Oncology Clinics of North America</i> , 2017 , 31, 681-692	3.1	31
109	A Randomized, Open-Label Study of Lestaurtinib (CEP-701), an Oral FLT3 Inhibitor, Administered in Sequence with Chemotherapy in Patients with Relapsed AML Harboring FLT3 Activating Mutations: Clinical Response Correlates with Successful FLT3 Inhibition.. <i>Blood</i> , 2005 , 106, 403-403	2.2	31
108	Results Of a Phase 2 Randomized, Open-Label, Study Of Lower Doses Of Quizartinib (AC220; ASP2689) In Subjects With FLT3-ITD Positive Relapsed Or Refractory Acute Myeloid Leukemia (AML). <i>Blood</i> , 2013 , 122, 494-494	2.2	31
107	Bench to bedside targeting of FLT3 in acute leukemia. <i>Current Drug Targets</i> , 2010 , 11, 781-9	3	31
106	Constitutive Fms-like tyrosine kinase 3 activation results in specific changes in gene expression in myeloid leukaemic cells. <i>British Journal of Haematology</i> , 2007 , 138, 603-15	4.5	27
105	Results of a first-in-human, phase I/II trial of ASP2215, a selective, potent inhibitor of FLT3/Axl in patients with relapsed or refractory (R/R) acute myeloid leukemia (AML).. <i>Journal of Clinical Oncology</i> , 2015 , 33, 7003-7003	2.2	27
104	Novel FLT3 tyrosine kinase inhibitors. <i>Expert Opinion on Investigational Drugs</i> , 2003 , 12, 1951-62	5.9	26
103	Small molecule FLT3 tyrosine kinase inhibitors. <i>Current Pharmaceutical Design</i> , 2004 , 10, 1183-93	3.3	26
102	Clinical implications of molecular markers in acute myeloid leukemia. <i>European Journal of Haematology</i> , 2019 , 102, 20-35	3.8	26
101	Improved FLT3 internal tandem duplication PCR assay predicts outcome after allogeneic transplant for acute myeloid leukemia. <i>Biology of Blood and Marrow Transplantation</i> , 2014 , 20, 1989-95	4.7	25
100	Advances in treating acute myeloid leukemia. <i>F1000prime Reports</i> , 2014 , 6, 96		25
99	Role of CYP3A4 in bone marrow microenvironment-mediated protection of FLT3/ITD AML from tyrosine kinase inhibitors. <i>Blood Advances</i> , 2019 , 3, 908-916	7.8	25
98	Blinatumomab in Combination with Immune Checkpoint Inhibitors of PD-1 and CTLA-4 in Adult Patients with Relapsed/Refractory (R/R) CD19 Positive B-Cell Acute Lymphoblastic Leukemia (ALL): Preliminary Results of a Phase I Study. <i>Blood</i> , 2018 , 132, 557-557	2.2	24
97	A Prospective Study of Peritransplant Sorafenib for Patients with FLT3-ITD Acute Myeloid Leukemia Undergoing Allogeneic Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2020 , 26, 300-306	4.7	24
96	Efficacy and Safety of Single-Agent Quizartinib (Q), a Potent and Selective FLT3 Inhibitor (FLT3i), in Patients (pts) with FLT3-Internal Tandem Duplication (FLT3-ITD)-Mutated Relapsed/Refractory (R/R) Acute Myeloid Leukemia (AML) Enrolled in the Global, Phase 3, Randomized Controlled Quantum-R Trial. <i>Blood</i> , 2019 , 133, 563-563	2.2	23

95	Adaptation to TKI Treatment Reactivates ERK Signaling in Tyrosine Kinase-Driven Leukemias and Other Malignancies. <i>Cancer Research</i> , 2017 , 77, 5554-5563	10.1	22
94	FLT3 activating mutations display differential sensitivity to multiple tyrosine kinase inhibitors. <i>Oncotarget</i> , 2017 , 8, 10931-10944	3.3	22
93	Midostaurin after allogeneic stem cell transplant in patients with FLT3-internal tandem duplication-positive acute myeloid leukemia. <i>Bone Marrow Transplantation</i> , 2021 , 56, 1180-1189	4.4	22
92	FLT3 Inhibitor Maintenance After Allogeneic Transplantation: Is a Placebo-Controlled, Randomized Trial Ethical?. <i>Journal of Clinical Oncology</i> , 2019 , 37, 1604-1607	2.2	19
91	TTT-3002 is a novel FLT3 tyrosine kinase inhibitor with activity against FLT3-associated leukemias in vitro and in vivo. <i>Blood</i> , 2014 , 123, 1525-34	2.2	18
90	FLT3 kinase inhibitor TTT-3002 overcomes both activating and drug resistance mutations in FLT3 in acute myeloid leukemia. <i>Cancer Research</i> , 2014 , 74, 5206-17	10.1	18
89	The K666N mutation in SF3B1 is associated with increased progression of MDS and distinct RNA splicing. <i>Blood Advances</i> , 2020 , 4, 1192-1196	7.8	18
88	Cabozantinib is well tolerated in acute myeloid leukemia and effectively inhibits the resistance-conferring FLT3/tyrosine kinase domain/F691 mutation. <i>Cancer</i> , 2018 , 124, 306-314	6.4	17
87	Midostaurin treatment in FLT3-mutated acute myeloid leukemia and systemic mastocytosis. <i>Expert Review of Clinical Pharmacology</i> , 2017 , 10, 1177-1189	3.8	15
86	Pharmacokinetic Profile of Gilteritinib: A Novel FLT-3 Tyrosine Kinase Inhibitor. <i>Clinical Pharmacokinetics</i> , 2020 , 59, 1273-1290	6.2	15
85	Clinical activity of Crenolanib in patients with D835 mutant FLT3-positive relapsed/refractory acute myeloid leukemia (AML).. <i>Journal of Clinical Oncology</i> , 2014 , 32, 7027-7027	2.2	15
84	Laboratory and Clinical Investigations to Identify the Optimal Dosing Strategy for Quizartinib (AC220) Monotherapy in FLT3-ITD-Positive (+) Relapsed/Refractory (R/R) Acute Myeloid Leukemia (AML). <i>Blood</i> , 2016 , 128, 4042-4042	2.2	14
83	FLT3 inhibitors added to induction therapy induce deeper remissions. <i>Blood</i> , 2020 , 135, 75-78	2.2	13
82	Outcome of older (≥70 years) APL patients frontline treated with or without arsenic trioxide-an International Collaborative Study. <i>Leukemia</i> , 2020 , 34, 2333-2341	10.7	13
81	A phase 1/2 study of the oral FLT3 inhibitor pexidartinib in relapsed/refractory FLT3-ITD-mutant acute myeloid leukemia. <i>Blood Advances</i> , 2020 , 4, 1711-1721	7.8	12
80	Timed sequential therapy for acute myelogenous leukemia: Results of a retrospective study of 301 patients and review of the literature. <i>Leukemia Research</i> , 2017 , 61, 25-32	2.7	12
79	Lestaurtinib: a multi-targeted FLT3 inhibitor. <i>Expert Review of Hematology</i> , 2009 , 2, 17-26	2.8	12
78	Combination of ATO with FLT3 TKIs eliminates FLT3/ITD+ leukemia cells through reduced expression of FLT3. <i>Oncotarget</i> , 2018 , 9, 32885-32899	3.3	12

77	Recent advances in the development of small-molecule inhibitors for the treatment of acute myeloid leukemia. <i>Current Opinion in Hematology</i> , 2005 , 12, 55-61	3.3	11
76	Results From a Randomized Trial of Salvage Chemotherapy Followed by Lestaurtinib for FLT3 Mutant AML Patients in First Relapse.. <i>Blood</i> , 2009 , 114, 788-788	2.2	11
75	Hedgehog/GLI1 activation leads to leukemic transformation of myelodysplastic syndrome in vivo and GLI1 inhibition results in antitumor activity. <i>Oncogene</i> , 2019 , 38, 687-698	9.2	11
74	Potential targeting of FLT3 acute myeloid leukemia. <i>Haematologica</i> , 2021 , 106, 671-681	6.6	11
73	Quizartinib, a selective FLT3 inhibitor, maintains antileukemic activity in preclinical models of RAS-mediated midostaurin-resistant acute myeloid leukemia cells. <i>Oncotarget</i> , 2020 , 11, 943-955	3.3	10
72	A phase I/II study of the combination of quizartinib with azacitidine or low-dose cytarabine for the treatment of patients with acute myeloid leukemia and myelodysplastic syndrome. <i>Haematologica</i> , 2021 , 106, 2121-2130	6.6	10
71	Updates on targeted therapies for acute myeloid leukaemia. <i>British Journal of Haematology</i> , 2021 ,	4.5	10
70	Will newer tyrosine kinase inhibitors have an impact in AML?. <i>Best Practice and Research in Clinical Haematology</i> , 2010 , 23, 489-94	4.2	9
69	Lestaurtinib FLT3 Inhibitory Activity Is Modulated by Concomitant Azole Therapy and May Influence Relapse Risk.. <i>Blood</i> , 2009 , 114, 789-789	2.2	9
68	The Novel Inhibitor PLX3397 Effectively Inhibits FLT3-Mutant AML., <i>Blood</i> , 2011 , 118, 3632-3632	2.2	9
67	Addition of Sorafenib to Chemotherapy Improves the Overall Survival of Older Adults with FLT3-ITD Mutated Acute Myeloid Leukemia (AML) (Alliance C11001). <i>Blood</i> , 2015 , 126, 319-319	2.2	9
66	Quizartinib in acute myeloid leukemia. <i>Clinical Advances in Hematology and Oncology</i> , 2013 , 11, 586-8	0.6	9
65	A Novel Tandem Duplication Assay to Detect Minimal Residual Disease in FLT3/ITD AML. <i>Molecular Diagnosis and Therapy</i> , 2015 , 19, 409-17	4.5	8
64	Is targeted therapy feasible in acute myelogenous leukemia?. <i>Current Hematologic Malignancy Reports</i> , 2014 , 9, 118-27	4.4	8
63	Serum Flt3 ligand is a biomarker of progenitor cell mass and prognosis in acute myeloid leukemia. <i>Blood Advances</i> , 2019 , 3, 3052-3061	7.8	8
62	Allogeneic hematopoietic cell transplantation improves outcome of adults with t(6;9) acute myeloid leukemia: results from an international collaborative study. <i>Haematologica</i> , 2020 , 105, 161-169	6.6	8
61	Phase II Trial of Pembrolizumab after High-Dose Cytarabine in Relapsed/Refractory Acute Myeloid Leukemia. <i>Blood Cancer Discovery</i> , 2021 , 2, 616-629	7	8
60	Emerging molecular predictive and prognostic factors in acute myeloid leukemia. <i>Leukemia and Lymphoma</i> , 2018 , 59, 2021-2039	1.9	7

59	A Phase II Study of Midostaurin and 5-Azacitidine for Untreated Elderly and Unfit Patients With FLT3 Wild-type Acute Myelogenous Leukemia. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2020 , 20, 226-233.e7		
58	Immunomodulation with pomalidomide at early lymphocyte recovery after induction chemotherapy in newly diagnosed AML and high-risk MDS. <i>Leukemia</i> , 2020 , 34, 1563-1576	10.7	7
57	FLT3 tyrosine kinase inhibitors synergize with BCL-2 inhibition to eliminate FLT3/ITD acute leukemia cells through BIM activation. <i>Signal Transduction and Targeted Therapy</i> , 2021 , 6, 186	21	7
56	Phase 1 dose-escalation trial of clofarabine followed by escalating dose of fractionated cyclophosphamide in adults with relapsed or refractory acute leukaemias. <i>British Journal of Haematology</i> , 2012 , 158, 198-207	4.5	6
55	Clinical Pharmacokinetics and FLT3 Phosphorylation of AC220, a Highly Potent and Selective Inhibitor of FLT3. <i>Blood</i> , 2008 , 112, 2637-2637	2.2	6
54	Allogeneic transplantation for Ph+ acute lymphoblastic leukemia with posttransplantation cyclophosphamide. <i>Blood Advances</i> , 2020 , 4, 5078-5088	7.8	6
53	Clinical Outcomes in Patients with FLT3-ITD-Mutated Relapsed/Refractory Acute Myelogenous Leukemia Undergoing Hematopoietic Stem Cell Transplantation after Quizartinib or Salvage Chemotherapy in the QuANTUM-R Trial. <i>Transplantation and Cellular Therapy</i> , 2021 , 27, 153-162		5
52	FLT3 as a marker of minimal residual disease: Time to re-think?. <i>American Journal of Hematology</i> , 2017 , 92, 329-330	7.1	4
51	Related Nonmyeloablative Haploidentical (mini-haplo) Blood or Marrow Transplantation (BMT) with High-Dose Post-Transplant Cyclophosphamide (PTCy) for Acute Myeloid Leukemia (AML): Donor Age Impacts Outcome. <i>Blood</i> , 2015 , 126, 151-151	2.2	4
50	Pharmacokinetic Profile and Pharmacodynamic Effects of ASP2215, a Selective, Potent Inhibitor of FLT3/AXL, in Patients with Relapsed or Refractory Acute Myeloid Leukemia: Results from a First-in-Human Phase 1/2 Study. <i>Blood</i> , 2015 , 126, 4836-4836	2.2	4
49	Effect of quizartinib (AC220) on response rates and long-term survival in elderly patients with FLT3-ITD positive or negative relapsed/refractory acute myeloid leukemia.. <i>Journal of Clinical Oncology</i> , 2013 , 31, 7021-7021	2.2	4
48	Deletions in FLT-3 juxtamembrane domain define a new class of pathogenic mutations: case report and systematic analysis. <i>Blood Advances</i> , 2021 , 5, 2285-2293	7.8	4
47	Deep learning for diagnosis of acute promyelocytic leukemia via recognition of genomically imprinted morphologic features. <i>Npj Precision Oncology</i> , 2021 , 5, 38	9.8	4
46	Characteristics and outcome of patients with acute myeloid leukaemia and t(8;16)(p11;p13): results from an International Collaborative Study. <i>British Journal of Haematology</i> , 2021 , 192, 832-842	4.5	4
45	Follow-up of patients with R/R FLT3-mutation-positive AML treated with gilteritinib in the phase 3 ADMIRAL trial.. <i>Blood</i> , 2022 ,	2.2	3
44	Crenolanib Is A Highly Potent, Selective, FLT3 TKI with Activity Against D835 Mutations. <i>Blood</i> , 2012 , 120, 1341-1341	2.2	3
43	Efficacy and safety of quizartinib (AC220) in patients age ≥ 70 years with FLT3-ITD positive or negative relapsed/refractory acute myeloid leukemia (AML).. <i>Journal of Clinical Oncology</i> , 2013 , 31, 7023-7023 ³	2.2	3
42	FLT3 dancing on the stem cell. <i>Journal of Experimental Medicine</i> , 2017 , 214, 1857-1859	16.6	2

41	Tandem Duplication PCR (TD-PCR) Is a Novel Method of Detecting Minimal Residual Disease in FLT3/ITD AML and Is Highly Predictive of Relapse Risk Following Allogeneic Transplant.. <i>Blood</i> , 2012 , 120, 2479-2479	2.2	2
40	Liberal Vs. Restrictive Transfusion Thresholds in Leukemia Patients: A Feasibility Pilot Study. <i>Blood</i> , 2015 , 126, 771-771	2.2	2
39	Signaling Adaptation to TKI Treatment Reactivates ERK Signaling in FLT3/ITD Leukemia. <i>Blood</i> , 2016 , 128, 33-33	2.2	2
38	Novel FLT3 tyrosine kinase inhibitors		2
37	The impact of FLT3 mutation clearance and treatment response after gilteritinib therapy on overall survival in patients with FLT3 mutation-positive relapsed/refractory acute myeloid leukemia. <i>Cancer Medicine</i> , 2021 , 10, 797-805	4.8	2
36	Carotidynia Heraldng the Onset of Acute Leukemia. <i>American Journal of Medicine</i> , 2016 , 129, e43-5	2.4	2
35	Differentiation syndrome with lower-intensity treatments for acute myeloid leukemia. <i>American Journal of Hematology</i> , 2021 , 96, 735-746	7.1	2
34	Population Pharmacokinetic Analysis of Quizartinib in Healthy Volunteers and Patients With Relapsed/Refractory Acute Myeloid Leukemia. <i>Journal of Clinical Pharmacology</i> , 2020 , 60, 1629-1641	2.9	1
33	The current therapeutic landscape of FLT3 inhibitors. <i>Blood Advances</i> , 2017 , 1, 1944	7.8	1
32	Are FLT3 inhibitors likely to improve FLT3-mutated acute myeloid leukemia in the foreseeable future?. <i>International Journal of Hematologic Oncology</i> , 2013 , 2, 9-11	1	1
31	Phospho-specific flow: fixating on the target. <i>Clinical Cancer Research</i> , 2012 , 18, 1493-5	12.9	1
30	Chromosomal defects Detected by SNP-Array-Based Karyotyping Are Independent Predictors of Survival in Acute Myeloid Leukemia (AML). <i>Blood</i> , 2008 , 112, 431-431	2.2	1
29	Combination of Sorafenib and 5-Azacytidine Has Significant Activity in Patients with Relapsed/Refractory or Untreated Acute Myeloid Leukemia and FLT3-ITD mutation. <i>Blood</i> , 2012 , 120, 1519-1519	2.2	1
28	Constitutively Activating Mutations At the FLT3 Activation Loop Residue D835 Are Associated with Clinical Resistance to AC220. <i>Blood</i> , 2012 , 120, 674-674	2.2	1
27	TTT-3002 Is a Novel FLT3 Tyrosine Kinase Inhibitor That Has the Potential to Overcome Some of the Limitations of Current FLT3 Inhibitors in Treatment of Acute Myeloid Leukemia. <i>Blood</i> , 2012 , 120, 866-866	2.2	1
26	Variations in FLT3 ligand levels during the course of AML treatment.. <i>Journal of Clinical Oncology</i> , 2013 , 31, 7026-7026	2.2	1
25	Pre-Clinical Activity of Novel Hypoxia-Activated FLT3 Inhibitors in FLT3-Mutated AML. <i>Blood</i> , 2016 , 128, 5210-5210	2.2	1
24	Arsenic trioxide dose capping to decrease toxicity in the treatment of acute promyelocytic leukemia. <i>Journal of Oncology Pharmacy Practice</i> , 2021 , 10781552211024727	1.7	1

23	Concentration-QTc analysis of quizartinib in patients with relapsed/refractory acute myeloid leukemia. <i>Cancer Chemotherapy and Pharmacology</i> , 2021 , 87, 513-523	3.5	1
22	Phase 1 study of the histone deacetylase inhibitor entinostat plus clofarabine for poor-risk Philadelphia chromosome-negative (newly diagnosed older adults or adults with relapsed refractory disease) acute lymphoblastic leukemia or biphenotypic leukemia. <i>Leukemia Research</i> , 2021 , 110, 106707	2.7	1
21	A novel combination regimen of BET and FLT3 inhibition for FLT3-ITD acute myeloid leukemia. <i>Haematologica</i> , 2021 , 106, 1022-1033	6.6	1
20	Midostaurin for patients with acute myeloid leukemia and FLT3 mutations. <i>Clinical Advances in Hematology and Oncology</i> , 2019 , 17, 323-325	0.6	1
19	The role of the atypical chemokine receptor CCRL2 in myelodysplastic syndrome and secondary acute myeloid leukemia.. <i>Science Advances</i> , 2022 , 8, eabl8952	14.3	1
18	Glycosylation and Surface Localization Are Required for FLT3 Activation but Not for FLT3/ITD.. <i>Blood</i> , 2009 , 114, 2748-2748	2.2	0
17	Single-cell DNA sequencing reveals complex mechanisms of resistance to quizartinib. <i>Blood Advances</i> , 2021 , 5, 1437-1441	7.8	0
16	A method for overcoming plasma protein inhibition of tyrosine kinase inhibitors. <i>Blood Cancer Discovery</i> , 2021 , 2, 532-547	7	0
15	Arsenic and old. <i>Blood</i> , 2019 , 133, 1392-1393	2.2	
14	Kinase inhibitors in leukemia. <i>Advances in Pharmacology</i> , 2004 , 51, 1-33	5.7	
13	The Presence of SETBP1, RUNX1 or EZH2 Mutation in MDS/MPN Is Associated with Absence of Response to Hypo-Methylating Agents. <i>Blood</i> , 2021 , 138, 1520-1520	2.2	
12	Constitutive FLT3 Activation Results in Specific Changes in Gene Expression in Myeloid Leukemic Cells.. <i>Blood</i> , 2004 , 104, 1115-1115	2.2	
11	FLT3/ITD Expression Increases Expansion, Survival and Entry into Cell Cycle of Human Hematopoietic Stem Cells.. <i>Blood</i> , 2004 , 104, 484-484	2.2	
10	Bad Phosphorylation Is Reduced in Response to Inhibition of Constitutively Activated FLT3.. <i>Blood</i> , 2005 , 106, 1367-1367	2.2	
9	Phase II Clinical Trial of Flavopiridol (FL) Followed by ara-c and Mitoxantrone (AM) for Adults with Relapsed and Refractory Acute Leukemias.. <i>Blood</i> , 2005 , 106, 2784-2784	2.2	
8	Prolonged Exposure to FLT3 Inhibitors Leads to Resistance Via Activation of Parallel Signaling Pathways.. <i>Blood</i> , 2006 , 108, 1380-1380	2.2	
7	FLT3: A Prototype Receptor Tyrosine Kinase Target in AML 2007 , 247-261		
6	The Response of FLT3/ITD AML to FLT3 Inhibition: Apoptosis of Peripheral Blood Blasts and Differentiation of Bone Marrow Blasts. <i>Blood</i> , 2011 , 118, 943-943	2.2	

- 5 Statin Treatment Prevents FLT3 Glycosylation and Overcomes Resistance to FLT3 Tyrosine Kinase Inhibitors. *Blood*, **2011**, 118, 1421-1421 2.2
- 4 Final Report of Combination of Sorafenib, Idarubicin, and Cytarabine for Initial Therapy in Younger Patients with Acute Myeloid Leukemia. *Blood*, **2012**, 120, 1516-1516 2.2
- 3 Is there evidence for the use of FLT3 inhibitors as maintenance therapy in AML?. *Best Practice and Research in Clinical Haematology*, **2021**, 34, 101246 4.2
- 2 Arsenic and all- retinoic acid for acute promyelocytic leukemia: yes, it really is as good as it seems. *Haematologica*, **2021**, 106, 3031-3032 6.6
- 1 FLT3 and acute myeloid leukemia: what is the wild type receptor up to?. *Haematologica*, **2005**, 90, 1586 6.6